The U.S. Food and Drug Administration moved closer this month toward evaluating CBD for human foods, topicals and pet products, but consumers and regulators still have unanswered questions about its safety.
The FDA is looking at safe daily doses, the different forms of CBD products and any health threats that the substance might present. These include potential liver toxicity and male reproductive problems, as well as side effects such as drowsiness, the agency said in a report submitted to appropriations committees in the U.S. House and Senate.
“We have made progress, but there are still areas where timely attention is needed,” the agency said.
The FDA said it will produce a followup document for Congress within 180 days with the results of a sampling study of the current CBD marketplace “to determine the extent to which products are mislabeled or adulterated.”